7. Share ownership information
The tables in this section are audited by the external auditor.
31 March 2026 | 31 March 2025 | |||||||||||||||
Total Shares | of which Restricted Shares 1 | RSUs | Options | Total Shares | of which Restricted Shares 2 | RSUs | Options | |||||||||
Gilbert Achermann, Chair 3 | 22,520 | 2,250 | 9,771 | 501 | ||||||||||||
Gregory Behar, Member | 3,644 | 2,994 | 2,563 | 2,238 | ||||||||||||
Lynn Dorsey Bleil, Member | 8,377 | 2,994 | 7,621 | 2,969 | ||||||||||||
Roland Diggelmann, Member | 2,994 | 2,994 | 2,238 | 2,238 | ||||||||||||
Laura Stoltenberg, Member 4 | 756 | 756 | n/a | n/a | ||||||||||||
Julie Tay, Member | 3,015 | 2,515 | 1,759 | 1,759 | ||||||||||||
Ronald van der Vis, Member | 8,347 | 2,994 | 7,591 | 2,969 | ||||||||||||
Adrian Widmer, Member | 3,725 | 2,994 | 2,969 | 2,969 | ||||||||||||
Total (active members) | 53,378 | 20,491 | 34,512 | 15,643 | ||||||||||||
Other members that left during the financial year | n/a | n/a | 90,436 | 14,337 | ||||||||||||
Total | 53,378 | 20,491 | 124,948 | 29,980 | ||||||||||||
1These shares are subject to a restriction period which varies from 1 June 2026 to 1 June 2029, depending on the grant date. The restricted shares have full shareholder rights.
2These shares are subject to a restriction period which varies from 1 June, 2026 to 1 June, 2030 depending on the grant date. The restricted shares have full shareholder rights
3Board member from June 2024, Board Chair from June 2025.
4Board member from June 2025.
For further details see also Note 7.4 in the consolidated financial statements.
As of March 31, 2026, the shareholding requirements set by the share ownership guidelines are met by all members of the Board of Directors, except for one member who was marginally below the set target and impacted by the share price volatility in March 2026.
The tables in this section are audited by the external auditor.
The following tables show the equity of individual Group Executives and persons closely linked to them.
31 March 2026 | 31 March 2025 | |||||||||||||||
Shares 1 | PSUs | RSUs | Options | Shares 1 | PSUs | RSUs | Options | |||||||||
Eric Bernard2 Chief Executive Officer | 4,685 | 1,540 | - | 12,490 | n/a | n/a | n/a | n/a | ||||||||
Elodie Carr-Cingari 2 Chief Financial Officer | 500 | - | - | - | n/a | n/a | n/a | n/a | ||||||||
Lilika Beck President, Consumer Hearing | 121 | 492 | 177 | 4,846 | 492 | 298 | 4,846 | |||||||||
Roberto Di Fiore 3 Chief Operations Officer | - | - | - | - | n/a | n/a | n/a | n/a | ||||||||
Katya Kruglova Chief Human Resources Officer | 975 | 2,470 | - | 10,422 | 186 | 2,470 | 10,422 | |||||||||
Oliver Lux GVP Audiological Care | 848 | 657 | 276 | 8,797 | 661 | 657 | 463 | 8,797 | ||||||||
Anders Rosengren 4 Chief Research & Development Officer | - | - | 162 | 636 | n/a | n/a | n/a | n/a | ||||||||
Alistair Simpson President, Cochlear Implants | 130 | 605 | - | 2,596 | 605 | 2,596 | ||||||||||
Total (active members) | 7,259 | 5,764 | 615 | 39,787 | 847 | 4,224 | 761 | 26,661 | ||||||||
Other members that left during the financial year | n/a | n/a | n/a | n/a | 25,551 | 16,650 | 675 | 289,719 | ||||||||
Total (including members that left during the financial year) | 7,259 | 5,764 | 615 | 39,787 | 26,398 | 20,874 | 1,436 | 316,380 | ||||||||
1Shares are dividend entitled with full voting rights.
2Group Executive since July 2025.
3Group Executive since December 2025.
4Group Executive since October 2025
As of March 31, 2026, the shareholding requirements set by the share ownership guidelines are met by five Group Executives. Three Group Executives were marginally below the set target and impacted by the share price volatility in March 2026. As indicated previously, the target holding levels and build-up periods under the shareholding requirements for the Group Executives will be reset to align with market practice and to simplify the overall framework.
The following table shows a detailed breakdown of the outstanding options of Group Executives as of 31 March 2026.
31 March 2026 | ||||||||||||||||||
Options EEAP 25 1 | Options EEAP 24 2 | Options EEAP 23 3 | Options EEAP 22 4 | Options EEAP 21 5 | Options EEAP 20 6 | Options EEAP 19 7 | Options EEAP 18 8 | Total options | ||||||||||
Eric Bernard Chief Executive Officer | 12,490 | - | - | - | - | - | - | - | 12,490 | |||||||||
Other Group Executives | 10,945 | 5,870 | 4,204 | 1,117 | 1,611 | 2,115 | 1,435 | - | 27,297 | |||||||||
Total (active members) | 23,435 | 5,870 | 4,204 | 1,117 | 1,611 | 2,115 | 1,435 | - | 39,787 | |||||||||
Other members that left during the financial year | 17,432 | 22,251 | 26,069 | 13,872 | 29,720 | 33,787 | 38,184 | 85,656 | 266,971 | |||||||||
Total (including members that left during the financial year) | 40,867 | 28,121 | 30,273 | 14,989 | 31,331 | 35,902 | 39,619 | 85,656 | 306,758 | |||||||||
1Exercise price CHF 319.20, vesting period 1.2.2025–1.6.2029 whereas one tranche being vested each year, end of restriction period 31.1.2030, exercise period 1.2.2030–31.1.2035 and for CEO exercise price CHF 238.60, vesting period 1.7.2025–1.11.2029 whereas one tranche being vested each year, end of restriction period 30.6.2030, exercise period 1.7.2030–30.6.2035.
2Exercise price CHF 279.10, vesting period 1.2.2024–1.6.2028 whereas one tranche being vested each year, end of restriction period 31.1.2029, exercise period 1.2.2029–31.1.2034.
3Exercise price CHF 233.40 vesting period 1.2.2023–1.6.2027 whereas one tranche being vested each year, end of restriction period 31.1.2028, exercise period 1.2.2028–31.1.2033 and for one member exercise price CHF 278.20, vesting period 2.5.2023–1.6.2027 whereas one tranche being vested each year, end of restriction period 31.1.2028, exercise period 1.2.2028–31.1.2033.
4Exercise price CHF 333.60 vesting period 1.2.2022–1.6.2026 whereas one tranche being vested each year, end of restriction period 31.1.2027, exercise period 1.2.2027–31.1.2032.
5Exercise price CHF 218.70 vesting period 1.2.2021–1.6.2025 whereas one tranche being vested each year, end of restriction period 31.1.2026, exercise period 1.2.2026–31.1.2031.
6Exercise price CHF 241.80, vesting period 1.2.2020–1.6.2024 whereas one tranche being vested each year, end of restriction period 31.1.2025, exercise period 1.2.2025–31.1.2030.
7Exercise price CHF 182.40, vesting period 1.2.2019–1.6.2023 whereas one tranche being vested each year, exercise period 1.6.2020–31.1.2029.
8Includes the one-time, non-recurring performance option grant (46,528 options); exercise price of CHF 147.85, vesting period of 1.2.2018–1.4.2025, exercise period 1.4.2025–30.9.2027.
The following table shows a detailed breakdown of the outstanding options of Group Executives as of 31 March 2025.
31 March 2025 | ||||||||||||||||||
Options EEAP 25 1 | Options EEAP 24 2 | Options EEAP 23 3 | Options EEAP 22 4 | Options EEAP 21 5 | Options EEAP 20 6 | Options EEAP 19 7 | Options EEAP 18 9 | Total options | ||||||||||
Arnd Kaldowski | 16,768 | 18,400 | 21,832 | 13,274 | 25,454 | 28,119 | 32,901 | 85,656 | 242,404 | |||||||||
Other Group Executives | 15,872 | 16,703 | 11,005 | 9,548 | 6,347 | 7,783 | 6,718 | 73,976 | ||||||||||
Total (active members) | 32,640 | 35,103 | 32,837 | 22,822 | 31,801 | 35,902 | 39,619 | 85,656 | 316,380 | |||||||||
Other members that left during the financial year | 2,313 8 | 2,625 8 | 6,468 8 | 10,684 8 | 22,090 8 | |||||||||||||
Total (including members that left during the financial year) | 32,640 | 35,103 | 35,150 | 25,447 | 38,269 | 46,586 | 39,619 | 85,656 | 338,470 | |||||||||
1Exercise price CHF 319.20, vesting period 2025-02-01 to 2029-06-01 whereas one tranche being vested each year, end of restriction period 2030-01-31, exercise period 2030-02-01 to 2035-01-31.
2Exercise price CHF 279.10, vesting period 2024-02-01 to 2028-06-01 whereas one tranche being vested each year, end of restriction period 2029-01-31, exercise period 2029-02-01 to 2034-01-31.
3Exercise price CHF 233.40, vesting period 2023-02-01 to 2027-06-01 whereas one tranche being vested each year, end of restriction period 2028-01-31, exercise period 2028-02-01 to 2033-01-31 and for one member exercise price CHF 278.20, vesting period 2023.05.02 to 2027-06-01 whereas one tranche being vested each year, end of restriction period 2028-01-31, exercise period 2028-02-01 to 2033-01-31.
4Exercise price CHF 333.60, vesting period 2022-02-01 to 2026-06-01 whereas one tranche being vested each year, end of restriction period 2027-01-31, exercise period 2027-02-01 to 2032-01-31.
5Exercise price CHF 218.70, vesting period 2021-02-01 to 2025-06-01 whereas one tranche being vested each year, end of restriction period 2026-01-31, exercise period 2026-02-01 to 2031-01-31.
6Exercise price CHF 241.80, vesting period 2020-02-01-2024-06-01 whereas one tranche being vested each year, end of restriction period 2025-01-31, exercise period 2025-02-01 to 2030-01-31.
7Exercise price CHF 182.40, vesting period 2019-02-01-2023-06-01 whereas one tranche being vested each year, exercise period 2020-06-01-2029-01-31.
8For one member SARs were granted instead of options (SARs grant the right to participate in the appreciation of Sonova shares without issuance of shares).
9Includes the one-time, non-recurring performance option grant (46,528 options); exercise price of CHF 147.85, vesting period of 2018-02-01 to 2025-04-01, exercise period 2025-04-01 to 2027-09-30.